Deciphera presents results from ctDNA analysis of INTRIGUE Phase III in GIST

Deciphera Pharmaceuticals’ (Nasdaq: DCPH) shares rose 4.4% to $18.85 in after-hours trading yesterday, when the US biopharma company presented additional data from the planned exploratory analysis from the INTRIGUE Phase III clinical study of Qinlock (ripretinib) using circulating tumor DNA (ctDNA) from patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib.

The presentation titled Mutational heterogeneity of imatinib resistance and efficacy of ripretinib versus sunitinib [Pfizer's Sutnt] in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE was made by Dr Sebastian Bauer, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium at the American Society of Clinical Oncology (ASCO) Plenary Series Session.

Qinlock was approved by the US Food and Drug Administration in May 2020, with marketing authorizations following elsewhere, including in Europe, Canada and the UK. Analysts at Stifel expect peak sales of just $200 million for the drug, which assumes that ex-USA use will ramp to match US revenues.